Jubilant Pharmova Announces Results for FY 2026; Recommends Final Dividend of Rs. 5 Per Share
Jubilant Pharmova Limited announced on May 22, 2026, that its Board of Directors approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ending March 31, 2026. The company also recommended a final dividend of Rs. 5/- per equity share for the fiscal year ended March 31, 2026.The Board meeting, held on May 22, 2026, approved the financial results and noted the auditor's reports, which provided an unmodified opinion on the audited financial results. The company further fixed July 24, 2026, as the record date for the final dividend payment, subject to shareholder approval.
For the financial year ended March 31, 2026, the Board recommended a final dividend of Rs. 5/- (Rupees five) per equity share of face value of Re. 1 each. If approved by the shareholders, the dividend will be paid within 30 days from the date of the Annual General Meeting.
Financial Highlights (₹ in million)
The company released key financial metrics for the year ended March 31, 2026, comparing the audited results to the previous year.| Metric | Year Ended 31 March 2026 (Audited) | Year Ended 31 March 2025 (Audited) |
|---|---|---|
| Total Revenue from Operations | 82,796 | 72,345 |
| Total Income | 83,456 | 72,913 |
| Profit Before Tax (From Continuing Operations) | 6,141 | 9,806 |
| Total Assets | 155,221 | 127,564 |
| Total Equity and Liabilities | 70,956 | 62,386 |
Segment Performance
The consolidated audited financial results also provided segment revenue and profitability data for the period. Total revenue from operations reached ₹22,900 million for the quarter ended March 31, 2026, compared to ₹21,225 million in the quarter ended December 31, 2025, and ₹19,288 million in the quarter ended March 31, 2025.Consolidated revenue was robust across major segments:
- Therapy Immunotherapy: ₹7,957 million (Year Ended 31 March 2026)
- Contract Development and Manufacturing Organization - Sterile Injectables: ₹2,063 million (Year Ended 31 March 2026)
- Contract Research, Development and Manufacturing Organization: ₹1,238 million (Year Ended 31 March 2026)
- Generics: ₹11,522 million (Year Ended 31 March 2026)
Standalone Financial Picture
The standalone financial results for the year ended March 31, 2026, showed a total revenue from operations of ₹2,635 million, a slight increase from ₹2,314 million in the previous year. Profit before tax from continuing operations stood at ₹292 million, up from ₹414 million in the previous year.Audit Assurance
The company released audited financial results for both consolidated and standalone entities, with both reports confirming that the Statutory Auditors, M/s Walker Chandiok & Co. LLP, issued reports containing an unmodified opinion on the financial results for the financial year ended March 31, 2026.JUBLPHARMA Stock Price Movement
As of 3:14 PM, shares of Jubilant Pharmova Limited are slipping by 0.52% in live trading, currently at ₹1006.4. The stock is currently trading on high volume of 492,015 shares, having ranged significantly throughout the day between a low of ₹988 and a high of ₹1025.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: